Sign in →

Test Code MSFNG Fibronectin Glomerulopathy Confirmation, Mass Spectrometry


Necessary Information


Preliminary pathology report, history, and electron microscopy images are required.



Specimen Required


Supplies: Pathology Packaging Kit (T554)

Specimen Type: Formalin-fixed, paraffin-embedded kidney tissue block

Collection Instructions: Do not send fixed tissue slides. Testing can only be done on paraffin-embedded tissue blocks.


Secondary ID

615305

Useful For

Aiding in the diagnosis of fibronectin glomerulopathy

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
MLCPC Microdissection, Laser Capture No, (Bill Only) No
MSPTC Mass Spectrometry No, (Bill Only) No

Method Name

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

Reporting Name

FNG Confirm, LC MS

Specimen Type

Special

Specimen Stability Information

Specimen Type Temperature Time Special Container
Special Ambient (preferred)
  Frozen 
  Refrigerated 

Reject Due To

Fixed tissue slides
Wet/frozen tissue
Cytological smears
Nonformalin fixed tissue
Nonparaffin embedded tissue		 Reject

Clinical Information

Fibronectin glomerulopathy, also called glomerulopathy with fibronectin deposits 2 (GFND2), is a rare kidney disease characterized by large amounts of fibronectin deposits in the mesangium and subendothelial space of renal glomeruli. Liquid chromatography tandem mass spectrometry performed on microdissected glomeruli from patients with GFND2 demonstrates a unique proteomic profile. The presence of abnormal fibronectin deposits, in the appropriate clinical and pathological context, can be useful to establish a diagnosis of GFND2.

Interpretation

An interpretation will be provided.

Cautions

No significant cautionary statements

Clinical Reference

1. Lusco MA, Chen Y, Cheng H, et al. AJKD atlas of renal pathology: Fibronectin glomerulopathy. Am J Kidney Dis. 2017;70(5):e21-e22. doi:10.1053/j.ajkd.2017.09.001

2. Ishimoto I, Sohara E, Ito E, Okado T, Rai T, Uchida S. Fibronectin glomerulopathy. Clin Kidney J. 2013;6(5):513-515. doi:10.1093/ckj/sft097

3. Satoskar AA, Shapiro JP, Bott CN, et al. Characterization of glomerular diseases using proteomic analysis of laser capture microdissected glomeruli. Mod Path. 2012;25(5):709-721. doi:10.1038/modpathol.2011.205

4. Castelletti F, Donadelli R, Banterla F, et al. Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci U S A. 2008;105(7):2538-2543. doi:10.1073/pnas.0707730105

Method Description

Affected areas are removed from paraffin-embedded tissues by laser microdissection. Protein digestion is performed, followed by liquid chromatography tandem mass spectrometry.(Unpublished Mayo method)

Day(s) Performed

Monday through Friday

Report Available

7 to 15 days

Specimen Retention Time

Until Reported

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

82542

88380

LOINC Code Information

Test ID Test Order Name Order LOINC Value
MSFNG FNG Confirm, LC MS 65757-7

 

Result ID Test Result Name Result LOINC Value
615306 Interpretation 50595-8
615307 Participated in the Interpretation No LOINC Needed
615308 Report electronically signed by 19139-5
615309 Material Received 81178-6
615310 Disclaimer 62364-5
615311 Case Number 80398-1
617017 Gross Description 22634-0
617018 Addendum 35265-8